Finance

Cogent Biosciences: FDA Accepts Bezuclastinib NDA; Near-Term Catalysts Ahead

Cogent Biosciences’ NDA for bezuclastinib to treat Non-Advanced Systemic Mastocytosis has been accepted by the FDA, setting a PDUFA target of December 30, 2026 and signaling a near-term regulatory milestone. The company is also lining up NDAs for GIST and Advanced Systemic Mastocytosis in 2026, backed by a January Breakthrough Therapy Designation for the GIST program. Note that independent verification from the FDA listings or Cogent disclosures is pending.

📅 March 16, 2026
⏱️ 2 min read
Cogent Biosciences: FDA Accepts Bezuclastinib NDA; Near-Term Catalysts Ahead

Key Takeaways

  • FDA accepted the Non-AdvSM NDA, with a PDUFA date of December 30, 2026.
  • FDA indicated no advisory committee is planned for the Non-AdvSM review.
  • Cogent plans NDAs for GIST and AdvSM in 2026, with GIST backed by Breakthrough Therapy Designation.
  • Breakthrough Therapy Designation for GIST was granted in January for the bezuclastinib+sunitinib combo.
  • Stock rose ~5% to about $35.81; 12-month gain ~380%; analysts setting targets in the $50s to mid-$50s.

People Involved

  • No specific individuals mentioned

Entities Involved

  • Cogent Biosciences Inc. (COGT) Biotech company developing bezuclastinib programs
  • U.S. Food and Drug Administration (FDA) Regulatory agency evaluating the NDA and setting milestones

MarketMoodz Analysis

This development creates a clearer regulatory path and near-term catalysts for Cogent’s platform, expanding potential patient access beyond Non-AdvSM into GIST and AdvSM. With a PDUFA date in late 2026 and no advisory committee planned for this review, the NDA could move toward approval if safety and efficacy hold, reinforcing a multi-indication strategy.

Historically, NDA acceptances in rare KIT-driven disorders can unlock meaningful upside for biotech stocks, especially when paired with Breakthrough Therapy Designations that may accelerate development timelines. The stock’s move reflects anticipated upside but comes with biotechnology volatility and competition from other KIT inhibitors; investors should monitor upcoming data, regulatory updates, and potential additional NDAs to gauge ultimate upside.

Source: Original Article

Get AI-Powered Market Insights

Stay ahead of market-moving events with our real-time analysis and stock ratings.

Start Your Free Trial